title: Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?
authors.affiliation: Department of Woman, Children and General and Specialized Surgery, Second University of Naples, Via L. De Crecchio n 2 - 80138 Naples, Italy.
authors.forename: Velia
authors.initials: V
authors.lastname: D'Angelo
authors.forename: Maria
authors.initials: M
authors.lastname: Ramaglia
authors.forename: Adriana
authors.initials: A
authors.lastname: Iannotta
authors.forename: Raffaele
authors.initials: R
authors.lastname: Addeo
mesh_terms: D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005838:Genotype; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008107:Liver Diseases / Q000209:etiology; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics* / Q000378:metabolism; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D057285:Precision Medicine
chemical_list: D000964:Antimetabolites, Antineoplastic; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008727:Methotrexate
keywords: MTHFR polymorphisms; hematological malignancy; methotrexate; pharmacogenomic